Tempus AI signals beyond the news: 69+ signals from 7 sources
The latest Tempus AI signal on this page is from Nov 17, 2026 (Patents): "TEMPUS AI, INC.'s patent output is steady: 24 grants in the past year, 2 in the past 30 days." The busiest sources: Glassdoor (15+), LinkedIn (15+) and Website changes (15+).
Public (TEM)Biotechnology Research5,001 to 10,000 employeestempus.comLinkedIn
Get Tempus AI's live signals in Claude or ChatGPT, or by API
What changed at Tempus AI this week? Use Autobound signals for tempus.com.- Signals
- 69+
- Sources
- 7
- Last 90 days
- 37
- Latest
- Nov 17, 2026
Source: Autobound Signal API · 97 signals tracked for Tempus AI · updated
Other signals · latest 10
Latest Tempus AI signals by source
69+ signals for Tempus AI across 7 sources.
Patents · Patent pace
TEMPUS AI, INC.'s patent output is steady: 24 grants in the past year, 2 in the past 30 days.
Over the past year TEMPUS AI, INC. received 24 US patent grants, concentrated in health tech / medical informatics and software / computing; the recent pace (6 in 90 days) is steady versus its trailing baseline.
- Grants, 12 months
- 24
- Grants, 90 days
- 6
- Grants, 30 days
- 2
- USPTO assignee
- Tempus AI, Inc.
LinkedIn
Tempus AI launches Real-Time Variant Tracker as a supplement to xM NeXT Personal Dx.
xM (NeXT Personal® Dx) is a key part of the patient care continuum, providing crucial information during surveillance and monitoring for early-stage disease and for IO treatment response monitoring for late-stage disease. Now available to support your clinical insights, Real-Time Variant Tracker™ is a supplemental...
- Likes
- 71
- Comments
- 0
- Tags
- Medical Research, Pharmaceuticals
- Initiatives
- launch of Real-Time Variant Tracker
LinkedIn
Tempus will present six abstracts at the CTOS Annual Meeting on rare mesenchymal tumors.
Next week, Tempus will present six abstracts, including three oral presentations, at the Connective Tissue Oncology Society Annual Meeting (November 18–21). In rare diseases like sarcoma, small patient populations have historically created barriers to research. By leveraging our multimodal library, which includes...
- Likes
- 60
- Comments
- 1
- Tags
- Medical Research, Pharmaceuticals, Data Management
- Initiatives
- presenting six abstracts at CTOS meeting
Patents · Patent grant
Tempus AI was granted a patent for AI-based heart risk prediction.
In November 2026 Tempus AI patented a clinical tool for estimating coronary blood-flow health and cardiac-event risk from ECGs and patient records.
- Patent title
- Predicting fractional flow reserve from electrocardiograms and patient records
- Grant date
- Nov 10, 2026
- Inventors
- Kipp Johnson, Tanner Carbonati
Glassdoor · Compensation dissatisfaction
Employees report dissatisfaction with total compensation and lack of 401k matching program
Multiple employees cite low salary levels and a lack of 401k matching as significant pain points in their compensation packages.
- Overall rating
- 3.1 of 5
- CEO approval
- 44%
- Reviews read
- 7
- Review window
- Oct 20, 2026 to Nov 8, 2026
Glassdoor · Growth opportunities
Staff report limited career advancement paths outside of management tracks
Employees describe an environment where promotion to higher technical levels is made unnecessarily difficult and career paths are poorly defined.
- Overall rating
- 3.1 of 5
- CEO approval
- 44%
- Reviews read
- 7
- Review window
- Oct 20, 2026 to Nov 8, 2026
Product reviews · Pricing concerns
Verified User reports Tempus is expensive to use despite being cost-effective
A Verified User in Computer & Network Security at a Small-Business company notes that Tempus is expensive to use, although they deem it cost-effective overall. This indicates a potential barrier for some users or a concern regarding the cost-to-value ratio.
- Star rating
- 4 of 5
- Reviewer
- Verified User in Computer & Network Security
- Reviewer details
- Small-Business (50 or fewer emp.)
Reddit · Acquisition announced
Tempus has an agreed buyout offer to acquire Personalis at $16.25 per share, which is pending shareholder approval.
Post: "PSNL - a textbook case of reflexivity from Soros’ Alchemy of Finance?"
- Subreddit
- r/wallstreetbets
- Upvotes
- 1
- Comments
- 0
- Sentiment
- Neutral
YouTube
Tempus AI 60% Rocket! Buy TEM Stock Now! TEM Stock Analysis
Ez Money Show analyzes Tempus AI stock, discussing its potential as a portfolio investment.
- Channel
- Ez Money Show
- Views
- 23
- Comments
- 0
- Tags
- Stock Analysis, Biotechnology, Precision Medicine
Website changes · Product launch
No new products, services, or major feature launches are indicated in the recent website update.
The content remains focused on existing solutions, clinical data, and integration capabilities without mention of new offerings.
- Page
- /oncology
Showing 10 of 69+ signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Tempus AI with the Signal API
One POST /v1/companies/enrich call with tempus.com returns Tempus AI signals from 14 more signal types (reddit-company, podcast-company, glassdoor-company and more), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{
"domain": "tempus.com",
"signal_types": ["reddit-company","podcast-company","glassdoor-company",
"product-reviews","linkedin-post-company","twitter-company-posts",
"youtube-company","website-intelligence","patents-company",
"federal-contract-award","conference-speaker","hackernews",
"producthunt-launch","seo-traffic"],
"limit": 20
}'Bulk data
Need these signals for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file).
Same industry
Other signals at related companies
Questions about Tempus AI other signals
What signals does Autobound track for Tempus AI besides news and filings?
What are people saying about Tempus AI online?
What do employees say about working at Tempus AI?
Has Tempus AI been granted patents recently?
Page updated , the date of the newest row on this page.
Source. Reddit, podcasts, Glassdoor, product reviews, LinkedIn, X, YouTube, company websites, patents, federal contracts, conference talks, Hacker News, Product Hunt, web traffic and employee growth, from the Signal API.
Method. The latest 15 signals per source from the last 12 months. Posts that do not name the company, replies, repeats and unreadable rows are removed. Traffic and headcount keep their newest measure.
Data as of .